Steven Cohen Acadia Pharmaceuticals Inc Call Options Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$14.62 - $18.42 $175,440 - $221,040	12,000 Added 13.33%	102,000 $1.66 Million
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $1.6 Million - $2.78 Million	90,000 New	90,000 $1.66 Million
Q2 2021 Aug 16, 2021	SELL	$19.4 - $27.42 $3.86 Million - $5.45 Million	-198,900 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$25.02 - $54.99 $27,522 - $60,489	-1,100 Reduced 0.55%	198,900 $5.13 Million
Q3 2018 Nov 14, 2018	SELL	$13.03 - $21.81 $24.8 Million - $41.4 Million	-1,900,000 Reduced 90.48%	200,000 $4.15 Million
Q2 2018 Aug 14, 2018	BUY	$15.07 - $22.34 $31.6 Million - $46.9 Million	2,100,000 New	2,100,000 $32.1 Million

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.